Biotech Values

[mcbio]

Re: ABLX

My overall assessment of Ablynx is that is has some buyout vig, but not much else to make it attractive for investing. The main problem is competition: there are manifold companies developing small antibody-like drugs, and hence there’s a high probability that one or more of these techniques will prove to be better than nanobodies. Investing in Ablynx is (IMO) tantamount to a bet that some Big Pharma buys them out before it becomes common knowledge that another company’s platform is superior. This is not necessarily a bad bet, but it’s not a bet I’m inclined to make.

Is your investment thesis for ABLX still pretty much the same today? If nothing else, it sounds like an interesting technology and approach. Also, who do you see as ABLX's biggest competitors in the small antibody-like drug space? Finally, do you have a ballpark estimate on ABLX's market-cap off-hand? Y! doesn't have that basic information since the stock trades on a foreign exchange. Edit: I found their Web site and it looks like a ballpark of about $400 million if I read the number correctly and converted accurately from EURs to dollars.